Transcriptomic changes after CDK12/13 inhibition by SR-4835 in ovarian cancer cell lines

The identification of novel molecular drivers and the development of new state-of-the-art therapies are critical challenges in ovarian cancer treatment. The present study examined the transcriptomic changes of the dual CDK12/13-inhibitor SR-4835 in platinum-sensitive and platinum-resistant OC cell lines. Ovarian cancer cell lines (A2780, A2780 cis, SK-OV-3, Caov-3, Caov-3 cis) were treated for 24h with 90 nM SR-4835 and transcriptome profiling was performed.

鉴定新型分子驱动因子并开发新一代顶尖疗法，是卵巢癌治疗领域的核心挑战。本研究针对铂敏感型与铂耐药型卵巢癌（OC）细胞系，探究了双靶点细胞周期蛋白依赖性激酶12/13（CDK12/13）抑制剂SR-4835所诱导的转录组变化。实验中，我们采用90 nM浓度的SR-4835处理卵巢癌细胞系（A2780、A2780顺铂耐药株、SK-OV-3、Caov-3、Caov-3顺铂耐药株）24小时，随后完成转录组图谱分析。